Noticeably, the TIO3 was specially designed for the treatment of gliomas, and it was confirmed that it specifically inhibited the mRNA expression of TGF-β2 but not the expression of TGF-β1 and TGF-β3 (12). This evidence concerns the gene TGFB2 and central nervous system cancer.